Administration of all-trans retinoic acid after experimental traumatic brain injury is brain protective.
all-trans retinoic acid
apoptosis
astrogliosis
axonal injury
hippocampus
neuroinflammation
traumatic brain injury
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
16
09
2019
revised:
02
09
2020
accepted:
04
09
2020
pubmed:
24
9
2020
medline:
22
6
2021
entrez:
23
9
2020
Statut:
ppublish
Résumé
All-trans retinoic acid (ATRA) is a vitamin A metabolite, important in the developing and mature brain. Pre-injury ATRA administration ameliorates ischaemic brain insults in rodents. This study examined the effects of post-traumatic ATRA treatment in experimental traumatic brain injury (TBI). Male adult mice were subjected to the controlled cortical impact model of TBI or sham procedure and killed at 7 or 30 days post-injury (dpi). ATRA (10 mg kg-1, i.p.) was given immediately after the injury and 1, 2 and 3 dpi. Neurological function and sensorimotor coordination were evaluated. Brains were processed for (immuno-) histological, mRNA and protein analyses (qPCR and western blot). ATRA treatment reduced brain lesion size, reactive astrogliosis and axonal injury at 7 dpi, and hippocampal granule cell layer (GCL) integrity was protected at 7 and 30 dpi, independent of cell proliferation in neurogenic niches and blood-brain barrier damage. Neurological and motor deficits over time and the brain tissue loss at 30 dpi were not affected by ATRA treatment. ATRA decreased gene expression of markers for damage-associated molecular pattern (HMGB1), apoptosis (caspase-3 and Bax), activated microglia (TSPO), and reactive astrogliosis (GFAP, SerpinA3N) at 7 dpi and a subset of markers at 30 dpi (TSPO, GFAP). In experimental TBI, post-traumatic ATRA administration exerted brain protective effects, including long-term protection of GCL integrity, but did not affect neurological and motor deficits. Further investigations are required to optimize treatment regimens to enhance ATRA's brain protective effects and improve outcomes.
Sections du résumé
BACKGROUND AND PURPOSE
All-trans retinoic acid (ATRA) is a vitamin A metabolite, important in the developing and mature brain. Pre-injury ATRA administration ameliorates ischaemic brain insults in rodents. This study examined the effects of post-traumatic ATRA treatment in experimental traumatic brain injury (TBI).
EXPERIMENTAL APPROACH
Male adult mice were subjected to the controlled cortical impact model of TBI or sham procedure and killed at 7 or 30 days post-injury (dpi). ATRA (10 mg kg-1, i.p.) was given immediately after the injury and 1, 2 and 3 dpi. Neurological function and sensorimotor coordination were evaluated. Brains were processed for (immuno-) histological, mRNA and protein analyses (qPCR and western blot).
KEY RESULTS
ATRA treatment reduced brain lesion size, reactive astrogliosis and axonal injury at 7 dpi, and hippocampal granule cell layer (GCL) integrity was protected at 7 and 30 dpi, independent of cell proliferation in neurogenic niches and blood-brain barrier damage. Neurological and motor deficits over time and the brain tissue loss at 30 dpi were not affected by ATRA treatment. ATRA decreased gene expression of markers for damage-associated molecular pattern (HMGB1), apoptosis (caspase-3 and Bax), activated microglia (TSPO), and reactive astrogliosis (GFAP, SerpinA3N) at 7 dpi and a subset of markers at 30 dpi (TSPO, GFAP).
CONCLUSION AND IMPLICATIONS
In experimental TBI, post-traumatic ATRA administration exerted brain protective effects, including long-term protection of GCL integrity, but did not affect neurological and motor deficits. Further investigations are required to optimize treatment regimens to enhance ATRA's brain protective effects and improve outcomes.
Identifiants
pubmed: 32964418
doi: 10.1111/bph.15259
pmc: PMC7588818
doi:
Substances chimiques
Tretinoin
5688UTC01R
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5208-5223Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : SCHA1261/4-3
Organisme : China Scholarship Council
Informations de copyright
© 2020. The British Pharmacological Society.
Références
J Neurotrauma. 2009 Aug;26(8):1353-9
pubmed: 19344293
Neurochem Res. 2013 Dec;38(12):2604-15
pubmed: 24158695
Nat Rev Neurosci. 2007 Oct;8(10):755-65
pubmed: 17882253
Glia. 2005 Apr 1;50(1):21-31
pubmed: 15602748
J Cereb Blood Flow Metab. 2004 Feb;24(2):133-50
pubmed: 14747740
J Neurochem. 2010 Sep 1;114(5):1511-26
pubmed: 20557428
J Neurosci. 2018 Jun 6;38(23):5277-5288
pubmed: 29760176
Br J Pharmacol. 2016 Feb;173(4):692-702
pubmed: 25752446
PLoS One. 2012;7(8):e43829
pubmed: 22952778
Stem Cell Reports. 2018 Jun 5;10(6):1705-1720
pubmed: 29805108
BMC Neurosci. 2016 Jul 15;17(1):49
pubmed: 27422020
J Neurosci Res. 2008 Apr;86(5):1125-31
pubmed: 17975839
Drug Metab Dispos. 2000 Feb;28(2):205-8
pubmed: 10640519
PLoS One. 2012;7(7):e41892
pubmed: 22911864
Apoptosis. 2009 Nov;14(11):1289-98
pubmed: 19771521
J Neurosci Res. 2017 Mar;95(3):897-906
pubmed: 27448243
Cell Mol Life Sci. 2015 Apr;72(8):1559-76
pubmed: 25558812
Eur J Pharmacol. 2010 Jun 10;635(1-3):56-61
pubmed: 20303946
Br J Pharmacol. 2016 Feb;173(4):681-91
pubmed: 25939377
Nature. 2017 Jan 26;541(7638):481-487
pubmed: 28099414
Br J Pharmacol. 2019 Dec;176 Suppl 1:S297-S396
pubmed: 31710714
Leukemia. 2018 Jun;32(6):1277-1294
pubmed: 29743722
Br J Pharmacol. 2019 Dec;176 Suppl 1:S229-S246
pubmed: 31710718
J Neuroimmunol. 2016 Nov 15;300:21-29
pubmed: 27806872
Mol Imaging Biol. 2018 Feb;20(1):94-102
pubmed: 28695372
J Neurochem. 2017 Dec;143(5):523-533
pubmed: 28921587
Br J Pharmacol. 2020 Nov;177(22):5208-5223
pubmed: 32964418
J Neuroimmunol. 2006 Feb;171(1-2):135-44
pubmed: 16303184
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Front Immunol. 2016 Dec 05;7:556
pubmed: 27994591
Front Aging Neurosci. 2015 Mar 06;7:20
pubmed: 25798108
Int J Dev Neurosci. 1990;8(3):317-26
pubmed: 2201170
J Neuroinflammation. 2014 Jun 12;11:106
pubmed: 24924349
Nature. 2011 Mar 10;471(7337):220-4
pubmed: 21307853
J Neurosci. 2012 May 2;32(18):6391-410
pubmed: 22553043
Trends Pharmacol Sci. 2010 Dec;31(12):596-604
pubmed: 21035878
CNS Drugs. 2016 Sep;30(9):791-806
pubmed: 27339615
Glia. 2014 Jan;62(1):26-38
pubmed: 24166800
Mol Brain. 2018 Mar 13;11(1):14
pubmed: 29534734
J Neurotrauma. 2011 Mar;28(3):359-69
pubmed: 21190398
Immunity. 2017 Jun 20;46(6):957-967
pubmed: 28636962
J Neurochem. 2019 Jul;150(2):173-187
pubmed: 30790293
Neuromolecular Med. 2003;3(2):65-94
pubmed: 12728191
Nat Rev Neurol. 2017 Mar;13(3):171-191
pubmed: 28186177
J Biol Chem. 2015 Sep 11;290(37):22532-42
pubmed: 26240147
Braz J Med Biol Res. 2017 Apr 03;50(4):e5561
pubmed: 28380213
PLoS One. 2016 Sep 09;11(9):e0162626
pubmed: 27611191
Brain Struct Funct. 2017 Dec;222(9):4005-4021
pubmed: 28589257
J Neuroinflammation. 2019 Aug 31;16(1):175
pubmed: 31472680
Glia. 2017 Feb;65(2):278-292
pubmed: 27778404
Front Neurosci. 2019 Jan 23;13:07
pubmed: 30728762
Neurobiol Dis. 2010 Feb;37(2):267-74
pubmed: 19909815
J Neuroimmunol. 2013 Mar 15;256(1-2):1-6
pubmed: 23385081
Br J Pharmacol. 2020 Aug;177(16):3611-3616
pubmed: 32662875
Neurochem Res. 2018 Jun;43(6):1283-1296
pubmed: 29802528
J Histochem Cytochem. 2017 Feb;65(2):69-81
pubmed: 27856824
Cell Tissue Res. 2014 Aug;357(2):395-405
pubmed: 24715113
J Neurosci. 2015 Nov 25;35(47):15731-45
pubmed: 26609164
NeuroRx. 2004 Jan;1(1):5-16
pubmed: 15717003
Br J Pharmacol. 2018 Feb;175(3):407-411
pubmed: 29350411
J Neurotrauma. 2015 Nov 15;32(22):1777-88
pubmed: 26102571
Matrix Biol. 2018 Aug;68-69:571-588
pubmed: 29054751
J Neurotrauma. 2015 Oct 15;32(20):1599-607
pubmed: 25879397
Neurobiol Dis. 2012 Jun;46(3):745-58
pubmed: 22426396
Nat Rev Neurosci. 2013 Feb;14(2):128-42
pubmed: 23329160
J Cell Sci. 2002 Dec 15;115(Pt 24):4735-41
pubmed: 12432062
PLoS Biol. 2020 Jul 14;18(7):e3000410
pubmed: 32663219
Exp Brain Res. 2009 Mar;193(4):581-9
pubmed: 19050858
J Neurosci. 1997 Oct 1;17(19):7415-24
pubmed: 9295387
J Neuroinflammation. 2019 Aug 5;16(1):163
pubmed: 31383034
Pharmacol Res. 2015 Sep;99:125-36
pubmed: 26066585
Sci Rep. 2017 Jul 3;7(1):4512
pubmed: 28674431
Trends Neurosci. 2000 Feb;23(2):59
pubmed: 10652545
Lancet Public Health. 2016 Dec;1(2):e76-e83
pubmed: 29253420
J Exp Med. 2009 Sep 28;206(10):2131-9
pubmed: 19737861
J Neuroinflammation. 2016 Jun 07;13(1):140
pubmed: 27266706